

## COMPANY ANNOUNCEMENT NO.21/2016 10 November 2016

# Chr. Hansen closes acquisition of LGG®

Chr. Hansen has completed the previously announced acquisition of LGG<sup>®</sup>, the world's best documented probiotic strain, including trademarks and related business (cf. announcement no. 13/2016) for a cash consideration of EUR 73 million.

### CEO of Chr. Hansen Holding A/S, Cees de Jong

"With this acquisition, we strengthen our position in probiotic solutions for human health and dairy with attractive opportunities to fully leverage the potential of the LGG® brand both as a stand-alone product and in combination with Chr. Hansen's own strains such as the BB-12® strain".

The acquired business includes the LGG® trademarks and related royalties, a collection of around 3,200 strains and a small production site in Tikkurila, Finland, which currently produces the LGG® strain and a number of specialty strains for cheese, etc.

As part of the agreement Chr. Hansen and Valio will enter into a strategic R&D collaboration to extract further value within dairy, including commercialization of Valio's transglutaminase enzyme technologies.

#### For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations

Tel: +45 4574 7618

Camilla Lercke, Head of Media Relations

Tel: +45 5339 2384

#### Forward-looking statements

This announcement contains forward-looking statements. Such statements are subject to risks and uncertainties, as various factors, many of which are beyond the control of Chr. Hansen Holding A/S, may cause actual developments and results to differ materially from the expectations expressed in this announcement.

#### About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2015/16 financial year was EUR 949 million. The company has more than 2,700 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen. For further information, please visit www.chr-hansen.com.

Tel. +45 45 74 74 74 www.chr-hansen.com CVR-no: 28318677